Helix BioPharma Corp. announces the receipt of subscription agreements

Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for common shares and  warrants for aggregate net proceeds in excess of  CDN$4.6 million after expected expenses.

Helix BioPharma Corp. Completes Data Review of First Four Cohorts of its Phase I/II Clinical Study for Lung Cancer Drug Candidate L-DOS47

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed its interim review of the Company’s ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland (the “LDOS002 Study”). This review was not a formal analysis of data, …

Helix Biopharma Corp. Initiates Enrollment for Fifth Cohort in Polish Phase I/II Clinical Study of its Lung Cancer Drug Candidate L-DOS47

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the fifth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle …

Helix BioPharma Corp. to Conduct Interim Review of its LDOS002 Phase I/II Clinical Study

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the treatment of cancer, today announced that it has completed patient enrolment in the fourth cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 and will perform an interim review of data collected for all subjects enrolled to …

Helix BioPharma Corp. Establishes Polish Subsidiary

(Aurora, Ontario) – Helix BioPharma Corp. (“Helix”) (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has established a Polish subsidiary (“Helix Polska”). Helix Polska was established to facilitate and support ongoing clinical oncology research at leading research institutions in Poland.